MAR 16, 2018 10:21 PM PDT

The 'Triple Pill': A New Blood Pressure Treatment

WRITTEN BY: Nouran Amin

Even though there exists an abundance of blood pressure-lowering drugs, high blood pressure persists to be a health concern not only in the US but globally. Blood pressure can lead to heart attacks, kidney issues, as well as stroke; therefore, treating blood pressure is a crucial priority. On a global level, many suffering from high blood-pressure do not get the treatment they need. Many blood-pressure drugs require more than one medication of the treatment regimen. Unfortunately, this increases the complexity of the treatment process causing patients to forget to take their multiple blood-pressure medications.

To fix this issue, a study examined the efficacy of three drugs combined as one combination pill in treating blood pressure and compared these results in usual treatment care. The clinical trial performed was known as the TRIUMPH trial and was conducted in Sri Lanka on patients that have untreated high blood pressure with some having diabetes as well as chronic kidney disease.

Patients enrolled in the study have received either the usual blood pressure care or the combination pill. The combination pill better known as the ‘Triple Pill’ contains three blood pressure drugs: telmisartan, amlodipine, and chlorthalidone. These drugs utilize different blood-pressure reduction mechanisms but, they all work to relax the blood vessels.

The crucial difference between the two categories (triple pill vs. usual care) was the time it took to see results. Patients in the ‘usual care’ category took a longer time to achieve a health blood-pressure target in comparison to the patient receiving the Triple Pill. "Most people — 70 percent — reached blood pressure targets with the Triple Pill,” said study lead author Ruth Webster, MD, of The George Institute for Global Health. “The benefits were seen straight away and maintained until six months, whereas with usual care control rates were 55 percent at six months and even lower earlier in the trial."

Each of the drug used in the Triple Pill was in low dose but effective individually in reducing blood pressure. The particular use of each of these drugs was effective in preventing blood-pressure-related deaths and heart disease. When combining these drugs in the Triple Pill, studies showed that it results in synergistic effects.

The most appealing part of developing the Triple Pill is it’s accessibility in low-income areas as well globally in impoverished areas. It was evaluated as a new tool for care in a real-world setting. "The most urgent need for innovative strategies to control blood pressure is in low- and middle-income countries," says Webster. "The Triple Pill approach is an opportunity to 'leap frog' over traditional approaches to care and adopt an innovative approach that has been shown to be effective."

Lead researchers will conduct a follow-up qualitative study on thoughts concerning the Triple Pill. They will also examine the cost-effectiveness to evaluate if the Triple Pill is a cost-effective solution for controlling blood pressure. Furthermore, if the Triple Pill will serve as a global healthcare drug, then it is important to note that every nation varies on what they consider as a healthy blood pressure target.

Sources: American College of Cardiology, Science Daily

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUL 31, 2018
Drug Discovery
JUL 31, 2018
DNA For Drug Development?
Genetic data of individuals who were customers of DNA testing service for the purpose of understanding their ancestry and genetic history, such as the comp...
AUG 08, 2018
Videos
AUG 08, 2018
A Harbinger of Hope for Alzheimer's Patients?
The search for effective treatments for Alzheimer’s disease is ongoing, but overall, hasn’t been productive. Many companies, like pharmaceutica...
AUG 25, 2018
Videos
AUG 25, 2018
Engineering Targeted Nanoparticles
The Koch Institute at MIT has chosen one of Jason Chang's images as an Image Award recipient for 2018....
SEP 18, 2018
Drug Discovery
SEP 18, 2018
Clinical-Grade Drugs for Bone Diseases
According to a study published in Journal of Gerontology: Biological Sciences, a small molecule was discovered to play a role in bone formation, ultimately...
OCT 05, 2018
Cancer
OCT 05, 2018
FDA approves a new drug for an advanced type of skin cancer
As cancer is one of the most challenging diseases in our world, many efforts have been put into researching new ways for treatment to find new drugs that could help more patients worldwide. A...
OCT 06, 2018
Drug Discovery
OCT 06, 2018
New Class of Drugs for Breast Cancer Therapy
Scientists at Stevens Institute of Technology have designed a new class of molecules that may hold the potential to add to the arsenal of drugs actively be...
Loading Comments...